Theriva Biologics, Inc.

Healthcare · Biotechnology · United States

Last price 0.1825 USD (Oct 30, 2026, 10:05 AM EDT) · Market cap 8.38M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral c...